Volume 21 (2022)
Volume 20 (2021)
Volume 19 (2020)
Volume 18 (2019)
Volume 17 (2018)
Volume 16 (2017)
Volume 15 (2016)
Volume 14 (2015)
Volume 13 (2014)
Volume 12 (2013)
Volume 11 (2012)
Volume 10 (2011)
Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran

Nayyereh Ayati; Lora Fleifel; Shahdak Sharifi; Mohammad Sahraian; Shekoufeh Nikfar

Volume 20, Issue 3 , July 2021, , Pages 146-153


  Background: Cladribine tablets are the foremost oral immune-reconstitution therapy for high disease activity relapsing multiple sclerosis (HDA-RMS). We aimed to assess the cost-effectiveness of cladribine tablets compared to natalizumab in patients with HDA-RMS in Iran. Methods: A 5-year cohort-based ...  Read More

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis

Nayyereh Ayati; Saeed Taheri; Mohammad Ali Sahraian; Shekoufeh Nikfar

Volume 20, Issue 3 , July 2021, , Pages 154-161


  Background: The current study desired to conduct an economic analysis on ocrelizumab (OCR), a new relapsing multiple sclerosis (RMS) treatment strategy, in comparison to natalizumab (NTL), as one of the mostly-used disease-modifying therapies (DMTs) in Iran. Methods: A 31-health-state Markov model, based ...  Read More